| Ytd | 52.08% | |
| 1y | 891.58% |
| Open | 26.05 | Prev Close | 25.90 | Low | 25.96 | High | 27.46 | Mkt Cap | 949.99M |
| Vol | 437.46K | Avg Vol | 481.31K | EPS | -2.42 | P/E | -11.19 | Forward P/E | -1.43 |
| Beta | 1.04 | Short Ratio | 8.36 | Inst. Own | 91.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 23.34 | 200-d Avg | 18.70 | 1yr Est | 12.72 |
ANRO News
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company wit
On July 13, 2026, Alto Neuroscience, Inc. (the "Company") announced that, based upon prelimi
Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.80) per share which missed the analys
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with
Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision
— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole m
6,000,000 SharesCommon Stock Offered by the Selling StockholdersThis prospectus relates to the propo
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers
US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with
Jones Trading analyst Justin Walsh maintains Alto Neuroscience (NYSE:ANRO) with a Buy and lowers
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and lowers the
Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other s
Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo
— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoi
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and raises
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the
– Financing led by Commodore Capital with participation from new and existing biotech focused invest
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.45) per share which beat the analyst
BTIG analyst Thomas Shrader maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the pri